APLM vs ZYBT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
APLM's Piotroski F-Score of 3/9 indicates weak financial health, with significant red flags in profitability, cash flow, and leverage. The company exhibits extreme negative profitability metrics, including a -124.8% operating margin and -380.13% ROE, despite a 380.8% YoY revenue growth. With no Altman Z-Score available and a current ratio of 0.97, liquidity concerns persist. The stock trades at a high Price/Sales of 6.15 and a negative forward P/E of -30.62, suggesting valuation is driven by speculative growth expectations rather than fundamentals. The 52-week price range of $3.66 to $42.12 reflects extreme volatility, and the 5-year return of -98.0% underscores long-term underperformance.
ZYBT presents a high-risk profile characterized by a catastrophic price collapse and severe revenue contraction. While the Piotroski F-Score of 5/9 suggests stable internal financial health and the low Debt/Equity ratio (0.23) indicates minimal leverage, these are overshadowed by a -34.40% YoY revenue decline and negative operating margins. The stock is currently trading near its 52-week low after a massive 88.2% one-year decline, signaling a complete loss of investor confidence. Despite a low Price/Sales ratio of 0.28, the lack of growth and profitability makes the current valuation a value trap.
Compare Another Pair
Related Comparisons
APLM vs ZYBT: Head-to-Head Comparison
This page compares Apollomics, Inc. (APLM) and Zhengye Biotechnology Holding Limited (ZYBT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.